Data Presented at American Society of Hematology Meeting Demonstrate Potential Advantages of Factor D Inhibition for the Treatment of Complement Alternative Pathway-Mediated Diseases
05 déc. 2016 16h05 HE
|
Achillion Pharmaceuticals, Inc.
SAN DIEGO, Dec. 05, 2016 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) today announced novel research into complement biology that both expands the understanding of this...
Achillion Announces Upcoming Presentations of Novel Research Into Complement Biology at the 58th Annual Meeting of the American Society of Hematology
03 nov. 2016 09h01 HE
|
Achillion Pharmaceuticals, Inc.
NEW HAVEN, Conn., Nov. 03, 2016 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) today announced that two abstracts have been accepted for poster presentation at the...
Achillion Reports Third Quarter 2016 Financial Results And Provides Update On Clinical Programs
03 nov. 2016 09h00 HE
|
Achillion Pharmaceuticals, Inc.
Janssen HCV triple combination candidate JNJ-4178 reported 100% SVR12 after 6 weeks of therapy; global phase IIB study to begin 4Q 2016Achillion’s phase I MAD study with oral factor D inhibitor...
Achillion Presents Novel Research on Factor D Inhibition at the XXVIth International Complement Workshop
06 sept. 2016 06h05 HE
|
Achillion Pharmaceuticals, Inc.
NEW HAVEN, Conn., Sept. 06, 2016 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) today announced the presentation of two posters which detailed novel preclinical research into...
Achillion to Present at Two Upcoming Investor Conferences
01 sept. 2016 06h05 HE
|
Achillion Pharmaceuticals, Inc.
NEW HAVEN, Conn., Sept. 01, 2016 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) announced today that Milind Deshpande, Ph.D., President and Chief Executive Officer of Achillion,...
Achillion Announces Upcoming Presentation of Interim Phase 2a Results From the Janssen Sponsored Trial of Odalasvir, AL-335 and Simeprevir at the European Association for the Study of the Liver (EASL) Special Conference
11 août 2016 06h05 HE
|
Achillion Pharmaceuticals, Inc.
NEW HAVEN, Conn., Aug. 11, 2016 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) announced today that interim results from an ongoing phase 2a clinical trial, being conducted by...
Achillion to Present at the 2016 Wedbush PacGrow Healthcare Conference
09 août 2016 06h05 HE
|
Achillion Pharmaceuticals, Inc.
NEW HAVEN, Conn., Aug. 09, 2016 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) announced today that Milind Deshpande, Ph.D., President and Chief Executive Officer of Achillion,...
Achillion Reports Second Quarter 2016 Financial Results
04 août 2016 16h05 HE
|
Achillion Pharmaceuticals, Inc.
NEW HAVEN, Conn. , Aug. 04, 2016 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) today reported financial results for the three and six months ended June 30, 2016. For the second...
Achillion Presents Interim Phase 1 Results for ACH-4471, a Novel Orally-Administered Factor D Inhibitor, at the 21st Congress of the European Hematology Association
10 juin 2016 03h30 HE
|
Achillion Pharmaceuticals, Inc.
- Results indicate up to 100% inhibition of alternative-pathway (AP) activity in hemolysis and Wieslab assays after oral dosing of ACH-4471 - - Results support initiation...
Achillion Reports First Quarter 2016 Financial Results and Provides Update on Clinical Programs
03 mai 2016 06h05 HE
|
Achillion Pharmaceuticals, Inc.
- Company provides update on HCV collaboration with Janssen; Phase 2b combination study evaluating doublet and triplet regimens for six and eight weeks anticipated to begin in Q3 2016 – ...